Brave Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Brave Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-126	Closed	-$12K	–	222
2016 Q3	$12K	Hold	126	–	–	0.01%	311
2016 Q2	$11K	Buy	+126	New	+$11.3K	0.01%	323

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brave Asset Management's IBB Position: Q4 2016 in Review

Brave Asset Management sold out of iShares Biotechnology ETF (IBB) in Q4 2016, closing a stake of 126 shares — an estimated $12K sold.

Brave Asset Management first reported a position in IBB in Q2 2016 and held it in 2 quarters. The position peaked at $12K in Q3 2016. 522 funds tracked by Wall St. Rank hold IBB as of Q4 2016.

Brave Asset Management reported no remaining iShares Biotechnology ETF position as of Q4 2016 after selling out during the quarter.
Brave Asset Management sold 126 iShares Biotechnology ETF shares in Q4 2016, an estimated $12K.
Brave Asset Management first reported a position in iShares Biotechnology ETF in Q2 2016 and held it in 2 quarters.
Brave Asset Management's iShares Biotechnology ETF position peaked at $12K in Q3 2016.
522 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2016.

Based on Brave Asset Management's 13F filing for Q4 2016, filed 27 Jan 2017.